Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective

Figures

• 

  Fig. 1. Structure of the Markov model used for the cost-effectiveness analysis

• 

  Fig. 2. Preferred reporting items for systemic reviews and meta-analyses (PRISMA) flow diagram showing results of the search strategy

• 

  Fig. 3. Results from the cost-effectiveness analysis: per-patient costs according to treatment arm

• 

  Fig. 4. Tornado diagrams showing the main results from the one-way sensitivity analysis (OWSA). ICH intracranial heamorrhage, ICER incremental cost effectiveness ratio, ICUR incremental cost utility ratio, MB major bleeding, SE systemic embolism, LYs life-years, QALYs quality-adjusted life-years

• 

  Fig. 5. Cost-effectiveness plane resulting from the probabilistic sensitivity analysis (PSA). QALYs quality-adjusted life-years, WTP willingness-to-pay